BioSpace News Archive

Vapotherm, Inc. announced that it was notified on November 30, 2022 by the New York Stock Exchange, Inc. that the Company is not in compliance with the NYSE’s continued listing standard set forth in Section 802.01C of the NYSE’s Listed Company Manual because the average closing price of the Company’s common stock was less than $1.00 per share over a consecutive 30 trading-day period.

Endo International plc (OTC: ENDPQ) announced today that it will cease the production and sale of Endo Aesthetics’ Qwo® (collagenase clostridium histolyticum-aaes) in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloration.

Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced it has successfully completed its acquisition of Surgical Innovation Associates (SIA).

Iridex Corporation announced the Company plans to participate in a fireside chat with its covering equity research analyst from Stifel.

ProSomnus, Inc. (“the Company”), a pioneer in precision medical devices for the treatment of Obstructive Sleep Apnea (OSA), today announced the completion of its previously announced business combination with Lakeshore Acquisition I Corp. (“Lakeshore”) (Nasdaq: LAAA), a publicly traded special purpose acquisition company.

MediciNova, Inc. today announced that MediciNova’s Chief Medical Officer, Kazuko Matsuda, MD PhD MPH, presented positive results from a subgroup analysis of the completed Phase 2 clinical trial which evaluated MN-001 (tipelukast) for the treatment of hypertriglyceridemia at the International Diabetes Federation (IDF) World Diabetes Congress 2022 held online December 5 - 8, 2022.

Parnell Pharmaceuticals Holdings Ltd commenced its previously announced backstopped rights offering to raise gross proceeds of approximately US$4.0 million.

X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel small-molecule therapeutics to benefit people with diseases of the immune system, announced that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock.

Researchers at Exai Bio and UCSF have released data demonstrating that Exai’s novel, RNA-based liquid biopsy platform accurately detected breast cancer at the earliest stages and for the smallest tumors.

Cuidalas is a Cure Latam project that was born with the vision of improving the well-being and health of Colombian women, contributing to the early detection of breast cancer thanks to iBreastExam (iBE) certified technology, knowing awareness of social responsibility that each person has to take care of the health of their loved ones and also their own.